Adam F.'s questionable articles have really seemed to damage investor confidence. There's a looming sense that he could drop another hit piece at anytime. Fortunately the effect's of those hit pieces seem to be smaller and smaller. I do wish Dr. Peoples would have addressed Adam's criticism head on. Without taking Adam head on it leaves investors wondering if there is something to Adam's assertion. Could Galena have made a math mistake in the data as Adam seems to imply? Maybe. But that doesn't seem to make a bit of difference with regards to the science behind Neuvax.
Its always sound for a business like Gale to validate the science behind its potential products. Adam F's quistioning might short term seem damaging, but long term makes a very sound foundation for rises in pps, because investors now knowing (To an even highe degree) that NeuVax actually is a very attractice weapon against breastcancer.
Having in mind that Kriegsmann is a ( an ordinary) boardmember who 12 years ago was engaged in quistionable pumping a company like Gale, it is sound that discussions occour. Its good for Gale in the long run, because everybody gets their eyes open that Adam F's attacks has no substance
The interview was actually done last week. It wasn't posted until now because Brian said it took a while to edit. Several people have asked and he said he couldn't get back in touch after the article had been posted by Adam F
Thanks. I wonder why Dr. Peoples wouldn't get back in touch with him after Adam pointed out the discrepancies in the two studies? Seems like that would have a been a great opportunity clarify the inconsistencies. The science is definitely there, it's just concerning that the math/statistical issues hasn't been clarified by someone yet.